{"id":"W2791757400","doi":"10.1200/jco.2018.36.6_suppl.434","title":"Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Clinical endpoint; Metastatic Urothelial Carcinoma; Atezolizumab; Oncology; Progression-free survival; Neutropenia; Ramucirumab; Progressive disease; Population; Tolerability; Discontinuation; Febrile neutropenia; Gastroenterology; Pembrolizumab; Chemotherapy; Cancer; Randomized controlled trial; Adverse effect; Bladder cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002076769,0.001150259,0.002871229,0.0004905548,0.00028102,0.001001654,0.0005186435,0.0008892608,0.003518073],"category_scores_gemma":[0.001918273,0.0003607173,0.005002856,0.0004600539,0.000363888,0.0005485103,0.0004300581,0.001428378,0.0004098401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005519631,"about_ca_system_score_gemma":0.0007433327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006314757,"about_ca_topic_score_gemma":0.002991942,"domain_scores_codex":[0.999148,0.0004300399,0.0000924713,0.0001300177,0.00006242706,0.0001371348],"domain_scores_gemma":[0.9994447,0.000199518,0.0001346228,0.00007462015,0.00002782693,0.000118656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9443035,0.001352568,0.008019589,0.001274446,0.01220921,0.0001782277,0.00007656622,0.0007729269,0.003540069,0.0001202194,0.001021275,0.02713131],"study_design_scores_gemma":[0.8101862,0.1047187,0.04594688,0.000241852,0.03161728,0.0004543217,0.0001357662,0.001738873,0.001394544,0.0006661775,0.002832006,0.00006741423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98043,0.01467543,0.0004840964,0.0003277832,0.0002287547,0.001153549,0.001157008,0.00005803013,0.001485335],"genre_scores_gemma":[0.9939981,0.002462594,0.00037381,0.0003975063,0.000206728,0.0007695457,0.001033443,0.00001463303,0.0007436103],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003518073,"threshold_uncertainty_score":0.01176912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1271076608134585,"score_gpt":0.444385500738038,"score_spread":0.3172778399245796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}